17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
16:53 , Aug 18, 2017 |  BioCentury  |  Emerging Company Profile

Teasing out Th1

EpiThany Inc. aims to increase the potency of therapeutic cancer vaccines by designing antigens that selectively activate immune-stimulating Th1 cells, without incurring the immunosuppressive effects caused by Th2 cell activation. Like most cancer vaccines in...
07:00 , Mar 23, 2015 |  BioCentury  |  Finance

Alize's assets

French biotech Alize Pharma S.A.S. is employing an asset-centric model similar to those used by Atlas Venture or Index Ventures to maximize both capital efficiency and the attractiveness of the assets in its pipeline to...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

New Paradigm Therapeutics, Alize Pharma deal

Alize received exclusive, worldwide rights from New Paradigm Therapeutics to develop and commercialize peptides derived from a fragment of insulin-like growth factor (IGF) binding protein 2 (IGFBP2) peptides to treat osteoporosis and undisclosed rare indications...
07:00 , Jun 12, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Insulin-like growth factor binding protein 2 (IGFBP2) Mouse studies suggest an N-terminal IGFBP2 vaccine could help treat IGFBP2-overexpressing tumors. In mice with such tumors,...
08:00 , Mar 6, 2014 |  BC Innovations  |  Cover Story

Liver X receptor marks the spot

Multiple companies have shelved liver X receptor agonists for cardiovascular indications because of unfavorable effects on lipid levels. Now, a New York team and Rgenix Inc. have found a different role for the agonists in...
08:00 , Feb 23, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Insulin-like growth factor binding protein 2 (IGFBP2); integrin a5 (CD49e); integrin b1 (CD29); integrin-linked kinase (ILK); NF-kB Patient sample and mouse studies suggest...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

Hemispherx preclinical data

In an insulin-like growth factor binding protein 2 ( IGFBP2 ) transgenic mouse model of breast cancer, IGFBP2 antigens plus adjuvant Ampligen significantly inhibited tumor growth by 60% vs. 23% for mice treated with IGFBP2...
08:00 , Jan 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Insulin-like growth factor binding protein 2 (IGFBP2) Studies in mice suggest that IGFBP2 could help treat diabetes. In two mouse models of diabetes,...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Company News

Isis, OncoGenex Technologies deal

The partners amended a 2001 deal under which Isis received rights to co-develop and market OncoGenex’s OGX-011 . OncoGenex will now pay all development costs for the second-generation antisense inhibitor of clusterin mRNA . Originally,...